- Q4 2023 Mersana Therapeutics Inc Earnings Call TranscriptFeb 28, 2024$4.85 (+13.58%)Earnings
- Mersana Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Mersana Therapeutics Inc Earnings Call TranscriptNov 07, 2023$1.34 (-3.60%)Earnings
- Mersana Therapeutics Inc UPLIFT Data Update Call TranscriptJul 27, 2023
- Mersana Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Mersana Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Mersana Therapeutics Inc Earnings Call TranscriptMay 09, 2023$8 (+7.82%)Earnings
- Q4 2022 Mersana Therapeutics Inc Earnings Call TranscriptFeb 28, 2023$6.06 (+11.60%)Earnings
- Q3 2022 Mersana Therapeutics Inc Earnings Call TranscriptNov 07, 2022$6.64 (-11.94%)Earnings
- Mersana Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Mersana Therapeutics Inc Earnings Call TranscriptAug 08, 2022$5.25 (+4.17%)Earnings
- Mersana Therapeutics Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) TranscriptJun 02, 2022
- Q1 2022 Mersana Therapeutics Inc Earnings Call TranscriptMay 09, 2022$3.18 (-13.35%)Earnings
- Q4 2021 Mersana Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$4.39 (+7.33%)Earnings
- Mersana Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Mersana Therapeutics Inc at Stifel Healthcare Conference (Virtual) TranscriptNov 17, 2021
- Q3 2021 Mersana Therapeutics Inc Earnings Call TranscriptNov 09, 2021$9.52 (-0.94%)Earnings
- Mersana Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2021
- Mersana Therapeutics Inc UpRi Clinical Data Update Call TranscriptSep 10, 2021
- Q2 2021 Mersana Therapeutics Inc Earnings Call TranscriptAug 06, 2021$12.37 (+2.06%)Earnings
- Q1 2021 Mersana Therapeutics Inc Earnings Call TranscriptMay 10, 2021$14.92 (-3.24%)Earnings
- Mersana Therapeutics Inc Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Corporate Call TranscriptApr 16, 2021
- Q4 2020 Mersana Therapeutics Inc Earnings Call TranscriptFeb 26, 2021$18.18 (-1.03%)Earnings
- Mersana Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Mersana Therapeutics, Inc. - Special Call TranscriptJan 05, 2021
- Mersana Therapeutics, Inc. - Special Call TranscriptNov 16, 2020
- Mersana Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 11, 2020
- Q3 2020 Mersana Therapeutics Inc Earnings Call TranscriptNov 09, 2020$22.92 (+2.41%)Earnings
- Mersana Therapeutics, Inc. - Special Call TranscriptSep 17, 2020
- Q2 2020 Mersana Therapeutics Inc Earnings Call TranscriptAug 07, 2020$20.27 (-0.98%)Earnings
- Mersana Therapeutics Inc Annual Shareholders Meeting TranscriptJun 12, 2020
- Mersana Therapeutics, Inc. - Special Call TranscriptMay 27, 2020
- Q1 2020 Mersana Therapeutics Inc Earnings Call TranscriptMay 08, 2020$9.81 (-2.10%)Earnings
- Mersana Therapeutics, Inc. - Special Call TranscriptMar 30, 2020
- Q4 2019 Mersana Therapeutics Inc Earnings Call TranscriptFeb 28, 2020$8.66 (-1.03%)Earnings
- Mersana Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Q3 2019 Mersana Therapeutics Inc Earnings Call TranscriptNov 06, 2019$1.98 (+7.03%)Earnings
- Q2 2019 Mersana Therapeutics Inc Earnings Call TranscriptAug 08, 2019$3.16 (+3.95%)Earnings
- Q1 2019 Mersana Therapeutics Inc Earnings Call TranscriptMay 09, 2019$5.91 (+5.54%)Earnings
- Q4 2018 Mersana Therapeutics Inc Earnings Call TranscriptMar 08, 2019$4.52 (+7.11%)Earnings
Mersana Therapeutics Inc at Stifel Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everyone. My name is Alex Thompson; I'm an associate here on the biotech team at Stifel. It's my pleasure to introduce Anna Protopapas, President and CEO of Mersana Therapeutics. I'm going to throw it over to her to walk through an overview of the Company. Over to you, Anna.
Thank you, Alex, and thank you for having us here today.
Moving on to slide 2. Before I start, I just want to remind you that in this presentation, I will be making forward-looking statements. At Mersana, we aspire to ADC leadership by innovating to capture the full potential of this important therapeutic modality and ultimately make a real difference in patients. ADCs are a proven therapeutic modality. We have 11 on the market and over 100 in clinical development, but there is significant opportunity for ADCs to play an even bigger role in cancer treatment, and we want to be on the leading edge of this innovation.
With Dolaflexin,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)